These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 23797036)

  • 1. Targeting MET: why, where and how?
    Ghiso E; Giordano S
    Curr Opin Pharmacol; 2013 Aug; 13(4):511-8. PubMed ID: 23797036
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting the hepatocyte growth factor/Met pathway in cancer.
    De Silva DM; Roy A; Kato T; Cecchi F; Lee YH; Matsumoto K; Bottaro DP
    Biochem Soc Trans; 2017 Aug; 45(4):855-870. PubMed ID: 28673936
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The emerging role of MET/HGF inhibitors in oncology.
    Scagliotti GV; Novello S; von Pawel J
    Cancer Treat Rev; 2013 Nov; 39(7):793-801. PubMed ID: 23453860
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recent advances in the discovery of small molecule c-Met Kinase inhibitors.
    Parikh PK; Ghate MD
    Eur J Med Chem; 2018 Jan; 143():1103-1138. PubMed ID: 29157685
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting the MET gene for the treatment of non-small-cell lung cancer.
    Gelsomino F; Facchinetti F; Haspinger ER; Garassino MC; Trusolino L; De Braud F; Tiseo M
    Crit Rev Oncol Hematol; 2014 Feb; 89(2):284-99. PubMed ID: 24355409
    [TBL] [Abstract][Full Text] [Related]  

  • 6. c-Met and hepatocyte growth factor: potential as novel targets in cancer therapy.
    Sattler M; Salgia R
    Curr Oncol Rep; 2007 Mar; 9(2):102-8. PubMed ID: 17288874
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-c-MET Nanobody - a new potential drug in multiple myeloma treatment.
    Slørdahl TS; Denayer T; Moen SH; Standal T; Børset M; Ververken C; Rø TB
    Eur J Haematol; 2013 Nov; 91(5):399-410. PubMed ID: 23952536
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting receptor tyrosine kinase MET in cancer: small molecule inhibitors and clinical progress.
    Cui JJ
    J Med Chem; 2014 Jun; 57(11):4427-53. PubMed ID: 24320965
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of MET receptor tyrosine kinase and its ligand hepatocyte growth factor.
    Sadiq AA; Salgia R
    J Thorac Oncol; 2012 Dec; 7(16 Suppl 5):S372-4. PubMed ID: 23160322
    [No Abstract]   [Full Text] [Related]  

  • 10. Increased HGF Expression Induces Resistance to c-MET Tyrosine Kinase Inhibitors in Gastric Cancer.
    Ahn SY; Kim J; Kim MA; Choi J; Kim WH
    Anticancer Res; 2017 Mar; 37(3):1127-1138. PubMed ID: 28314274
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting the HGF/Met signaling pathway in cancer therapy.
    Cecchi F; Rabe DC; Bottaro DP
    Expert Opin Ther Targets; 2012 Jun; 16(6):553-72. PubMed ID: 22530990
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The current state of molecularly targeted drugs targeting HGF/Met.
    Yano S; Nakagawa T
    Jpn J Clin Oncol; 2014 Jan; 44(1):9-12. PubMed ID: 24371262
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dual inhibition of Met kinase and angiogenesis to overcome HGF-induced EGFR-TKI resistance in EGFR mutant lung cancer.
    Takeuchi S; Wang W; Li Q; Yamada T; Kita K; Donev IS; Nakamura T; Matsumoto K; Shimizu E; Nishioka Y; Sone S; Nakagawa T; Uenaka T; Yano S
    Am J Pathol; 2012 Sep; 181(3):1034-43. PubMed ID: 22789825
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting MET for glioma therapy.
    Awad AJ; Burns TC; Zhang Y; Abounader R
    Neurosurg Focus; 2014 Dec; 37(6):E10. PubMed ID: 25434379
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel therapeutic inhibitors of the c-Met signaling pathway in cancer.
    Eder JP; Vande Woude GF; Boerner SA; LoRusso PM
    Clin Cancer Res; 2009 Apr; 15(7):2207-14. PubMed ID: 19318488
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Progress in cancer therapy targeting c-Met signaling pathway.
    Jung KH; Park BH; Hong SS
    Arch Pharm Res; 2012 Mar; 35(4):595-604. PubMed ID: 22553051
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Developing c-MET pathway inhibitors for cancer therapy: progress and challenges.
    Liu X; Newton RC; Scherle PA
    Trends Mol Med; 2010 Jan; 16(1):37-45. PubMed ID: 20031486
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Review of clinic trials: agents targeting c-Met.
    Abidoye O; Murukurthy N; Salgia R
    Rev Recent Clin Trials; 2007 May; 2(2):143-7. PubMed ID: 18473999
    [TBL] [Abstract][Full Text] [Related]  

  • 19. C-MET as a potential target therapy toward personalized therapy in some pediatric tumors: An overview.
    Rashed WM
    Crit Rev Oncol Hematol; 2018 Nov; 131():7-15. PubMed ID: 30293708
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatocyte growth factor, its receptor, and their potential value in cancer therapies.
    Jiang WG; Martin TA; Parr C; Davies G; Matsumoto K; Nakamura T
    Crit Rev Oncol Hematol; 2005 Jan; 53(1):35-69. PubMed ID: 15607934
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.